- Home
- NI vs UTHR Comparison
NI vs UTHR Comparison
Compare NI & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NI
- UTHR
- Stock Information
- Founded
- NI 1912
- UTHR 1996
- Country
- NI United States
- UTHR United States
- Employees
- NI N/A
- UTHR N/A
- Industry
- NI Power Generation
- UTHR Biotechnology: Pharmaceutical Preparations
- Sector
- NI Utilities
- UTHR Health Care
- Exchange
- NI Nasdaq
- UTHR Nasdaq
- Market Cap
- NI 20.1B
- UTHR 20.7B
- IPO Year
- NI N/A
- UTHR 1999
- Fundamental
- Price
- NI $44.01
- UTHR $431.38
- Analyst Decision
- NI Buy
- UTHR Buy
- Analyst Count
- NI 9
- UTHR 15
- Target Price
- NI $44.44
- UTHR $466.73
- AVG Volume (30 Days)
- NI 4.3M
- UTHR 760.7K
- Earning Date
- NI 10-29-2025
- UTHR 10-29-2025
- Dividend Yield
- NI 2.59%
- UTHR N/A
- EPS Growth
- NI 16.92
- UTHR 17.94
- EPS
- NI 1.90
- UTHR 25.63
- Revenue
- NI $6,130,300,000.00
- UTHR $3,077,800,000.00
- Revenue This Year
- NI $16.39
- UTHR $13.71
- Revenue Next Year
- NI $4.28
- UTHR $5.72
- P/E Ratio
- NI $22.77
- UTHR $16.91
- Revenue Growth
- NI 16.98
- UTHR 17.62
- 52 Week Low
- NI $34.23
- UTHR $266.98
- 52 Week High
- NI $44.52
- UTHR $459.48
- Technical
- Relative Strength Index (RSI)
- NI 61.74
- UTHR 55.78
- Support Level
- NI $42.95
- UTHR $427.86
- Resistance Level
- NI $44.05
- UTHR $441.78
- Average True Range (ATR)
- NI 0.75
- UTHR 11.13
- MACD
- NI 0.00
- UTHR -5.24
- Stochastic Oscillator
- NI 73.63
- UTHR 30.27
About NI NiSource Inc
NiSource is one of the nation's largest natural gas distribution companies with 3.2 million customers in Indiana, Kentucky, Maryland, Ohio, Pennsylvania, and Virginia. NiSource's electric utility transmits and distributes electricity in northern Indiana to about 500,000 customers. The regulated electric utility also owns more than 3,000 megawatts of generation capacity, including coal, natural gas, and renewable energy.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.